Status:

COMPLETED

Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis

Lead Sponsor:

American Regent, Inc.

Conditions:

Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a open-label, prospective study comparing intravenous (IV) iron supplementation to standard care in anemic patents undergoing peritoneal dialysis.

Detailed Description

This is an open-label, prospective study comparing IV iron supplementation to standard care in anemic patients undergoing peritoneal dialysis. After successfully completing a 6 month enrollment period...

Eligibility Criteria

Inclusion

  • Hemoglobin \>= 9.5 and \<= 11.5 g/dL.
  • Ferritin \<= 500 ng/ml.
  • Serum Transferrin Saturation (TSAT) \<= 25%.
  • Stable erythropoietin (EPO) Regimen for 8 weeks.
  • No iron for last 4 weeks before randomization.

Exclusion

  • Known Sensitivity to Iron Sucrose.
  • Suffering concomitant severe diseases of the liver \& cardiovascular system.
  • Pregnancy / Lactation.
  • Inadequate dialysis.
  • Current treatment for asthma.
  • Significant blood loss.
  • Probability of need for transfusion or transfusion within 1 week of enrollment.
  • Anticipated major surgery.
  • Hemochromatosis / hemosiderosis.

Key Trial Info

Start Date :

July 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2004

Estimated Enrollment :

121 Patients enrolled

Trial Details

Trial ID

NCT00236938

Start Date

July 1 2002

End Date

October 1 2004

Last Update

May 19 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis | DecenTrialz